Personalized or Precision Medicine in the Dietary Approach to Obesity
NCT05420311 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 450
Last updated 2022-09-26
Summary
The main objective of this project is to apply a precision medicine approach to try to explain the intra-individual variability of the response to different weight loss approaches: a balanced hypocaloric diet in macronutrients (MedDiet), a very low carbohydrate diet (KetoDiet) and an intermittent fasting (IF) approach, and try to establish in a personalized manner with the individual variability in genetics, metabolites, intestinal microbiome, and environmental factors the best dietary strategy for weight loss. As secondary objectives the investigators pretend to O1: To analyze whether individual variability in genetics, epigenetics, intestinal microbiome, and environmental factors determine the changes in insulin resistance, blood pressure, lipid levels and NASH markers after three different dietary interventions. O2: To analyze whether individual variability in genetics, epigenetics, intestinal microbiome, and environmental factors determine the changes in the body composition and the different ratio of free-fat/ fat mass loss after three different dietary interventions. O3: To determine the most effective intervention to increase the loss of fat mass, preserve the free-fat mass and trigger a better metabolic profile. O4: To follow-up changes in gut microbiota and DNA methylation after each of the cross-over dietary interventions. O5: To evaluate the transcriptional response of adipose tissue and elucidate its predictive value for the body-composition changes in patients subjected to the different dietary interventions.
O6: To evaluate the influence of D-ß-hydroxybutyrate as well as other short-chain acyl-CoA precursor metabolites in human adipocytes lipolysis by in vitro experimentation and elucidate the influence of metabolite-sensitive histone modifications in the shaping of adipose transcriptional program and lipolysis sensitivity. O7: To develop a machine learning algorithm based on genetics, epigenetics, intestinal microbiome, and environmental factors for the prediction of the best dietary approach for weight loss in a personalized manner. To try to respond to these objectives, the investigators will apply two models: a randomized cross-over study testing three different dietary weight-loss interventions: MedDiet, KetoDiet, and IF with wash-out periods before each intervention.
Conditions
Interventions
- OTHER
-
MedDiet Arm
A balanced hypocaloric diet in macronutrients (MedDiet)
- OTHER
-
KetoDiet Arm
A very low carbohydrate diet (KetoDiet).
- OTHER
-
IF Arm
An intermittent fasting (IF) approach
Sponsors & Collaborators
-
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
lead OTHER
Principal Investigators
-
Franscisco J. Tinahones, MD, PhD. · Instituto de Investigacion Biomedica de Malaga
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-10-31
- Primary Completion
- 2024-07-01
- Completion
- 2024-12-01
Countries
- Spain
Study Locations
More Related Trials
-
Individualized Obesity Pharmacotherapy
NCT03374956 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
NCT04575194 ·Status: UNKNOWN ·Phase: PHASE4
-
Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg
NCT03534310 ·Status: COMPLETED ·Phase: NA
-
Impact of Satiating Compounds and Hypocaloric Diet on Weight, Cardiometabolic and Osteoarticular Health in Obesity
NCT07165548 ·Status: RECRUITING ·Phase: NA
-
Lifestyle Modification and Liraglutide
NCT02911818 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of ATL-962 in Obese Diabetics
NCT00156897 ·Status: COMPLETED ·Phase: PHASE2
-
A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
NCT00108524 ·Status: COMPLETED ·Phase: NA
-
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
NCT05129891 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of a Novel Precision Medicine Approach For Obesity
NCT06814938 ·Status: RECRUITING ·Phase: PHASE4
-
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
NCT03041792 ·Status: COMPLETED ·Phase: PHASE1
-
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6
NCT04687540 ·Status: COMPLETED ·Phase: NA
-
A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
NCT07194317 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
NCT05564117 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of ALT-801 in the Treatment of Obesity
NCT05295875 ·Status: COMPLETED ·Phase: PHASE2
-
Study Exploring the Supportive Effect of Acarbose in Weight Management
NCT05934110 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
NCT05429593 ·Status: COMPLETED ·Phase: PHASE1
-
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
NCT04521751 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548987 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06703021 ·Status: COMPLETED ·Phase: PHASE2
-
Vagal Blocking for Obesity Control
NCT00555958 ·Status: UNKNOWN ·Phase: NA
-
Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss
NCT02954627 ·Status: COMPLETED
-
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
NCT01905956 ·Status: COMPLETED ·Phase: PHASE3
-
3mg Liraglutide for Overweight or Obesity
NCT03885297 ·Status: COMPLETED
-
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
NCT00483171 ·Status: TERMINATED ·Phase: PHASE3